<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7113931/table_4" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 4</label>
  <p>Regimen-specific recommendations for use of RAS testing in clinical practice[ 
   <a rid="ref61" ref-type="bibr">61</a>] 
  </p>
 </caption>
 <thead>
  <tr>
   <th align="left" rowspan="1" colspan="1" id="0-0-.">Recommended</th>
   <th align="center" rowspan="1" colspan="1" id="0-1-.">*Rating</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="left" rowspan="1" colspan="1">Elbasvir/grazoprevir 
    <br/> NS5A RAS testing is recommended for genotype 1a-infected, treatment-naive or -experienced patients being considered for elbasvir/grazoprevir. If present, a different regimen should be considered. 
   </td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Ledipasvir/sofosbuvir 
    <br/> NS5A RAS testing can be considered for genotype 1a-infected, treatment-experienced patients without cirrhosis being considered for ledipasvir/sofosbuvir. If clinically importanta resistance is present, a different recommended therapy should be used. 
    <br/> NS5A RAS testing can be considered for genotype 1a-infected, treatment-experienced patients with cirrhosis being considered for ledipasvir/sofosbuvir. If clinically importanta resistance is present, a different recommended therapy should be used. 
   </td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Sofosbuvir/velpatasvir 
    <br/> NS5A RAS testing is recommended for genotype 3-infected, treatment-naive patients with cirrhosis and treatment-experienced patients (with or without cirrhosis) being considered for 12 weeks of sofosbuvir/velpatasvir. If Y93H is present, weight-based ribavirin should be added or sofosbuvir/velpatasvir/voxilaprevir should be used. 
   </td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Daclatasvir plus sofosbuvir 
    <br/> NS5A RAS testing is recommended for genotype 3-infected, treatment-experienced patients without cirrhosis being considered for 12 weeks of daclatasvir plus sofosbuvir. If Y93H is present, weight-based ribavirin should be added. 
    <br/> NS5A RAS testing is recommended for genotype 3-infected, treatment-naive patients with cirrhosis being considered for 24 weeks of daclatasvir plus sofosbuvir. If Y93H is present, treatment should include weight-based ribavirin, or a different recommended therapy used 
   </td>
   <td align="center" rowspan="1" colspan="1">I, B</td>
  </tr>
  <tr>
   <td align="center" colspan="2" rowspan="1">
    <hr/>
   </td>
  </tr>
  <tr>
   <td align="left" colspan="2" rowspan="1">
    <b>NOT RECOMMENDED</b>
   </td>
  </tr>
  <tr>
   <td align="center" colspan="2" rowspan="1">
    <hr/>
   </td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Elbasvir/grazoprevir 
    <br/> RAS testing is not recommended for any genotype 1b-infected patients being considered for elbasvir/grazoprevir therapy. 
   </td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Glecaprevir/pibrentasvir 
    <br/> RAS testing is not recommended for patients with genotype 1, 2, 3, 4, 5, or 6 infection being considered for glecaprevir/pibrentasvir for 8, 12, or 16 weeks 
   </td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Ledipasvir/sofosbuvir 
    <br/> NS5A RAS testing is not recommended for any genotype 1b-infected patients being considered for ledipasvir/sofosbuvir therapy. 
   </td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1"> NS5A RAS testing is not recommended for genotype 1a-infected, treatment-naive patients being considered for ledipasvir/sofosbuvir therapy</td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1"> NS5A RAS testing is not recommended for genotype 1a- or 1b-infected, treatment-naive patients without cirrhosis and with a viral load &lt;6 million IU/mL being considered for an 8-week course of ledipasvir/sofosbuvir therapy.</td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Paritaprevir/ritonavir/ombitasvir with dasabuvir±weight-based ribavirin, or paritaprevir/ritonavir/ombitasvir + weight-based ribavirin 
    <br/> RAS testing is not recommended for genotype 1- or 4-infected, treatment-naive or -experienced patients being considered for therapy with paritaprevir/ritonavir/ombitasvir with dasabuvir±weight-based ribavirin or paritaprevir/ritonavir/ombitasvir + weight-based ribavirin, respectively. 
   </td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Sofosbuvir/velpatasvir 
    <br/> RAS testing is not recommended for patients with genotype 1, 2, 4, 5, or 6 infection and considered for 12 weeks of sofosbuvir/velpatasvir therapy. 
   </td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Sofosbuvir/velpatasvir/voxilaprevir 
    <br/> RAS testing is not recommended for patients with genotype 1, 2, 3, 4, 5, or 6 infection and considered for 12 weeks of sofosbuvir/velpatasvir/voxilaprevir therapy. 
   </td>
   <td align="center" rowspan="1" colspan="1">I, A</td>
  </tr>
  <tr>
   <td align="left" colspan="2" rowspan="1">Clinically important=greater than 100-fold resistance</td>
  </tr>
 </tbody>
 <tfoot>
  <p class="fn" charset="fn">
   <p>*I: Evidence and/or general agreement that a given diagnostic evaluation, procedure, or treatment is beneficial, useful, and effective; A: Data derived from multiple randomized clinical trials, meta-analyses, or equivalent; B: Data derived from a single randomized trial, nonrandomized studies, or equivalent</p>
  </p>
 </tfoot>
</table>
